Effect of a Monoclonal Antibody to PCSK9 on Low-Density Lipoprotein Cholesterol Levels in Statin-Intolerant Patients

Abstract

Reduction of low-density lipoprotein cholesterol (LDL-C) is the cornerstone of cardiovascular risk reduction,^1-3 with specific LDL-C goals based on cardiovascular outcome trials.^1-4 Statins are currently the most effective agents for reducing LDL-C levels.⁵ However, of approximately 20 million patients treated with statins,⁶ an estimated 10% to 20% are unable to tolerate any statins or the higher doses necessary to achieve current LDL-C goals, primarily because of muscle-related side effects.⁷